| Literature DB >> 31386020 |
Emmanuel Mandonnet1, Michel Wager1, Fabien Almairac1, Marie-Helene Baron1, Marie Blonski1, Christian F Freyschlag1, Fabio Barone1, Denys Fontaine1, Johan Pallud1, Monika Hegi1, Catarina Viegas1, Maria Zetterling1, Giannantonio Spena1, John Goodden1, Geert-Jan Rutten1, Luc Taillandier1, Nicolas Foroglu1, Amélie Darlix1, Miran Skrap1, Juan Martino1, Gord von Campe1, Caterina Madadaki1, Etienne Gayat1, Philip de Witt Hamer1, Santiago Gil Robles1, Silvio Sarubbo1, Thomas Santarius1, Lorenzo Bello1, Marie-Therese Forster1, Hugues Duffau1.
Abstract
Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.Entities:
Keywords: GLIOCOM; diffuse low-grade glioma; evidence-based medicine; surgery; survey
Year: 2017 PMID： 31386020 PMCID： PMC6655513 DOI： 10.1093/nop/npw031
Source DB: PubMed Journal: Neurooncol Pract ISSN： 2054-2577